NICE Surgical Awarded Additional Purse-String Stapler Associated U.S. Patent

Rhea-AI Summary

NICE Surgical Solutions, a clinical-stage medical device company, has been granted U.S. Patent No. 12,661,097 B2 for an extracting device used with its purse-string stapler, designed to generally eliminate surgical incisions in colorectal surgery by enabling tissue extraction through the intra-anal canal.

The patent covers the extraction device and its introducer, which, together with NICE Surgical's existing patented purse-string stapler, allows colorectal procedures and tissue retrieval to be performed fully intracorporeally and minimally invasively. NICE Surgical is a portfolio company of Trendlines Medical Singapore, a subsidiary of The Trendlines Group (OTCQX: TRNLY, TRNGF), an investment company focused on medtech and agrifood innovation.

Positive

• U.S. Patent 12,661,097 B2 granted for NICE Surgical’s extraction device used with its purse-string stapler
• Technology enables fully intracorporeal, minimally invasive colorectal surgery without abdominal incision, potentially reducing infection risk
• NICE Surgical is a portfolio company of The Trendlines Group (TRNLY, TRNGF), adding another patented asset to Trendlines’ medtech portfolio

Negative

• None.

Market Context

OFSTF was down -1.78% at publication, while the momentum scanner listed no peers. Against that backd...

Analysis

OFSTF was down -1.78% at publication, while the momentum scanner listed no peers. Against that backdrop, the patent award stood apart from a documented sector move; low short positioning was the available risk context to monitor.

Key Figures

U.S. patent number: 12,661,097 B2 Patented solutions: Two patents Announcement date: July 20, 2026

3 metrics

U.S. patent number 12,661,097 B2 Granted for NICE Surgical's extracting device

Patented solutions Two patents NICE Surgical solutions awarded U.S. patents in quick succession

Announcement date July 20, 2026 Singapore announcement

Key Terms

intracorporeal anastomosis, purse-string stapler, introducer

3 terms

intracorporeal anastomosis medical

"clinical-stage medical device company pioneering full intracorporeal anastomosis surgical instruments"

A surgical technique that reconnects two internal hollow organs — most often segments of intestine — entirely inside the body during minimally invasive procedures, rather than bringing the ends out through an incision. Think of it as joining two garden hoses inside a closed box instead of disconnecting them to work on the ends; it can reduce wound size and speed recovery. For investors, this matters because the approach can change procedure time, complication rates, device and robotic-tool demand, hospital costs, and payer reimbursement, all of which affect market adoption and revenue potential.

purse-string stapler medical

"used in conjunction with its novel purse-string stapler"

A purse-string stapler is a surgical device that places a circular row of staples or fasteners around the edge of a tissue opening, much like drawing a drawstring purse closed, to cinch and seal the opening quickly and evenly. Investors care because it is a specialized medical tool used in common procedures, so its sales, regulatory approvals, or manufacturing changes can affect a device maker’s revenue, clinical adoption and reimbursement prospects.

introducer technical

"along with its introducer that, when used with NICE's purse-string stapler"

An introducer is a person or firm that brings potential clients to a financial services provider—such as a broker, fund manager, or adviser—by making referrals or introductions. Like a trusted friend who recommends a service, an introducer connects customers but usually does not handle the client’s money or carry out transactions; they often earn a referral fee or commission. Investors see introducers in notices because they affect how and through whom services are offered, and they can influence fees and transparency.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Enables natural orifice extraction of tissue without surgical incision

SINGAPORE, July 20, 2026 /PRNewswire/ -- NICE Surgical Solutions Pte Ltd ("NICE Surgical"), a clinical-stage medical device company pioneering full intracorporeal anastomosis surgical instruments, has been granted U.S. Patent No. 12,661,097 B2, for its extracting device used in conjunction with its novel purse-string stapler, generally eliminating the need for surgical incisions in colorectal surgery.

The patent covers NICE's extraction device design, along with its introducer that, when used with NICE's purse-string stapler, allows extraction of excised colon tissue through the intra-anal canal. The award of the patent validates NICE Surgical's strength in developing proprietary medical solutions to improve quality of life by mitigating the risk of infection prevalent to these surgeries.

The patented technology, together with its patented purse-string stapler, enables colorectal surgery and retrieval of excised tissue to be completed fully intracorporeally and minimally invasively, without an incision to the abdomen, as currently practiced. 

NICE Surgical is a portfolio company of Trendlines Medical Singapore Pte Ltd ("Trendlines Medical Singapore"), a subsidiary of The Trendlines Group Ltd (SGX: 42T) (OTCQX: TRNLY), ("Trendlines"), an investment company focused on medtech and agrifood innovation. 

"We are excited that two of our innovative solutions were awarded U.S. patents in quick succession. Innovation in colorectal surgery is not about adopting the newest technology—it is about advancing safer surgery, faster recovery, and better lives for every patient," commented Co-founder and Inventor, Eric Haas, MD, Chief of Colorectal Surgery, Houston Methodist Hospital.

Haim Brosh, CEO of Trendlines added, "NICE surgical truly embraces a keen innovative mindset and delivered the utmost in terms of design and development of its purse-string stapler and its extracting device. The award of the U.S. patent cements the resolve of NICE Surgical in bringing better solutions to the practice of medicine."

About The Trendlines Group Ltd.

The Trendlines Group (SGX: 42T) (OTCQX: TRNLY) invests in and develops innovations in agrifood and medtech, transforming early-stage technologies into impactful businesses. With operations in Israel and Singapore, Trendlines combines capital, expertise, and strategic partnerships to drive growth, advance global sustainability, and create long-term value for shareholders.

About NICE Surgical Solutions Pte Ltd

NICE Surgical is developing a stapling device that serves to divide the bowel at the proximal and distal level of resection as well as place a 'purse-string suture' to prepare the bowel for the Intra Corporeal Anastomosis (ICA). The stapling device accomplishes two critical tasks by simultaneously stapling closed the specimen while applying a 'purse-string suture' to the portion of the bowel to be used for an end-to-end circular stapled anastomosis.

Media contact:
Eric Loh
CEO Trendlines Medical Singapore
eric@trendlines.com

 

 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/nice-surgical-awarded-additional-purse-string-stapler-associated-us-patent-302829408.html

SOURCE NICE Surgical Solutions Pte Ltd

FAQ

What U.S. patent was awarded to NICE Surgical Solutions in July 2026?

NICE Surgical Solutions was awarded U.S. Patent No. 12,661,097 B2 for its colorectal tissue extraction device. According to NICE Surgical, the device works with its purse-string stapler to enable natural orifice tissue extraction and minimize the need for abdominal incisions.

How does NICE Surgical’s purse-string stapler technology change colorectal surgery?

NICE Surgical’s purse-string stapler allows full intracorporeal anastomosis and tissue retrieval without abdominal incisions. According to NICE Surgical, using the stapler with its patented extracting device enables minimally invasive colorectal surgery and extraction of excised colon tissue through the intra-anal canal.

What does NICE Surgical’s new U.S. patent mean for Trendlines (OTCQX: TRNLY, TRNGF) investors?

The new U.S. patent adds a protected technology asset to Trendlines’ medtech portfolio via NICE Surgical. According to Trendlines, the patent supports proprietary solutions aimed at safer colorectal surgery, which may strengthen Trendlines Medical Singapore’s innovation-focused investment strategy over the long term.

How does NICE Surgical’s patented device enable natural orifice tissue extraction in colorectal surgery?

NICE Surgical’s extracting device and introducer are designed to remove excised colon tissue through the intra-anal canal. According to NICE Surgical, when combined with its purse-string stapler, this system generally eliminates the need for separate abdominal surgical incisions in colorectal procedures.

Is NICE Surgical Solutions publicly traded like The Trendlines Group (TRNLY, TRNGF)?

NICE Surgical Solutions is described as a portfolio company of Trendlines Medical Singapore, not as a listed entity. According to Trendlines, The Trendlines Group is the publicly traded investment company focused on medtech and agrifood that holds NICE Surgical through its subsidiary.

What clinical benefits does NICE Surgical aim for with its patented colorectal surgery devices?

NICE Surgical aims to support safer surgery, faster recovery, and better patient outcomes with its devices. According to NICE Surgical, enabling fully intracorporeal, minimally invasive colorectal surgery may mitigate infection risk commonly associated with abdominal incisions in current practice.